These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
433 related articles for article (PubMed ID: 15243524)
1. Topical tacrolimus therapy for vitiligo: therapeutic responses and skin messenger RNA expression of proinflammatory cytokines. Grimes PE; Morris R; Avaniss-Aghajani E; Soriano T; Meraz M; Metzger A J Am Acad Dermatol; 2004 Jul; 51(1):52-61. PubMed ID: 15243524 [TBL] [Abstract][Full Text] [Related]
2. Analysis of interleukin-10 levels in lesions of vitiligo following treatment with topical tacrolimus. Taher ZA; Lauzon G; Maguiness S; Dytoc MT Br J Dermatol; 2009 Sep; 161(3):654-9. PubMed ID: 19438859 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of topical tacrolimus for the treatment of face and neck vitiligo. Lo YH; Cheng GS; Huang CC; Chang WY; Wu CS J Dermatol; 2010 Feb; 37(2):125-9. PubMed ID: 20175845 [TBL] [Abstract][Full Text] [Related]
4. Occlusive treatment enhances efficacy of tacrolimus 0.1% ointment in adult patients with vitiligo: results of a placebo-controlled 12-month prospective study. Hartmann A; Bröcker EB; Hamm H Acta Derm Venereol; 2008; 88(5):474-9. PubMed ID: 18779885 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of tarcrolimus cream 0.1% in the treatment of vitiligo. Xu AE; Zhang DM; Wei XD; Huang B; Lu LJ Int J Dermatol; 2009 Jan; 48(1):86-90. PubMed ID: 19126059 [TBL] [Abstract][Full Text] [Related]
6. An open randomized study to compare narrow band UVB, topical pimecrolimus and topical tacrolimus in the treatment of vitiligo. Stinco G; Piccirillo F; Forcione M; Valent F; Patrone P Eur J Dermatol; 2009; 19(6):588-93. PubMed ID: 19651562 [TBL] [Abstract][Full Text] [Related]
7. Response of vitiligo to once- vs. twice-daily topical tacrolimus: a controlled prospective, randomized, observer-blinded trial. Radakovic S; Breier-Maly J; Konschitzky R; Kittler H; Sator P; Hoenigsmann H; Tanew A J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):951-3. PubMed ID: 19496898 [TBL] [Abstract][Full Text] [Related]
8. Topical tacrolimus for treatment of childhood vitiligo in Asians. Kanwar AJ; Dogra S; Parsad D Clin Exp Dermatol; 2004 Nov; 29(6):589-92. PubMed ID: 15550128 [TBL] [Abstract][Full Text] [Related]
9. Topical tacrolimus and the 308-nm excimer laser: a synergistic combination for the treatment of vitiligo. Passeron T; Ostovari N; Zakaria W; Fontas E; Larrouy JC; Lacour JP; Ortonne JP Arch Dermatol; 2004 Sep; 140(9):1065-9. PubMed ID: 15381545 [TBL] [Abstract][Full Text] [Related]
10. Narrow-band UVB phototherapy combined with tacrolimus ointment in vitiligo: a review of 110 patients. Fai D; Cassano N; Vena GA J Eur Acad Dermatol Venereol; 2007 Aug; 21(7):916-20. PubMed ID: 17659000 [TBL] [Abstract][Full Text] [Related]
11. Interferon (IFN)-gamma , tumor necrosis factor-alpha , interleukin-6, and IFN-gamma receptor 1 are the major immunological determinants associated with post-kala azar dermal leishmaniasis. Ansari NA; Ramesh V; Salotra P J Infect Dis; 2006 Oct; 194(7):958-65. PubMed ID: 16960784 [TBL] [Abstract][Full Text] [Related]
12. Resolution of endothelial activation and down-regulation of Tie2 receptor in psoriatic skin after infliximab therapy. Markham T; Mullan R; Golden-Mason L; Rogers S; Bresnihan B; Fitzgerald O; Fearon U; Veale DJ J Am Acad Dermatol; 2006 Jun; 54(6):1003-12. PubMed ID: 16713454 [TBL] [Abstract][Full Text] [Related]
13. Decreased proinflammatory cytokine production by peripheral blood mononuclear cells from vitiligo patients following aspirin treatment. Zailaie MZ Saudi Med J; 2005 May; 26(5):799-805. PubMed ID: 15951873 [TBL] [Abstract][Full Text] [Related]
14. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside. O'Malley BW; Li D; McQuone SJ; Ralston R Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147 [TBL] [Abstract][Full Text] [Related]
15. Quantitative gene expression of cytokines in peripheral blood leukocytes stimulated in vitro: modulation by the anti-tumor nerosis factor-alpha antibody infliximab and comparison with the mucosal cytokine expression in patients with ulcerative colitis. Moriconi F; Raddatz D; Ho NA; Yeruva S; Dudas J; Ramadori G Transl Res; 2007 Oct; 150(4):223-32. PubMed ID: 17900510 [TBL] [Abstract][Full Text] [Related]
16. A double-blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo. Lepe V; Moncada B; Castanedo-Cazares JP; Torres-Alvarez MB; Ortiz CA; Torres-Rubalcava AB Arch Dermatol; 2003 May; 139(5):581-5. PubMed ID: 12756094 [TBL] [Abstract][Full Text] [Related]
17. Time-kinetic study of repigmentation in vitiligo patients by tacrolimus or pimecrolimus. Lubaki LJ; Ghanem G; Vereecken P; Fouty E; Benammar L; Vadoud-Seyedi J; Dell'Anna ML; Briganti S; Picardo M; Heenen M Arch Dermatol Res; 2010 Mar; 302(2):131-7. PubMed ID: 19547993 [TBL] [Abstract][Full Text] [Related]
18. FK506 promotes melanocyte and melanoblast growth and creates a favourable milieu for cell migration via keratinocytes: possible mechanisms of how tacrolimus ointment induces repigmentation in patients with vitiligo. Lan CC; Chen GS; Chiou MH; Wu CS; Chang CH; Yu HS Br J Dermatol; 2005 Sep; 153(3):498-505. PubMed ID: 16120133 [TBL] [Abstract][Full Text] [Related]
19. Tacrolimus ointment promotes repigmentation of vitiligo in children: a review of 57 cases. Silverberg NB; Lin P; Travis L; Farley-Li J; Mancini AJ; Wagner AM; Chamlin SL; Paller AS J Am Acad Dermatol; 2004 Nov; 51(5):760-6. PubMed ID: 15523355 [TBL] [Abstract][Full Text] [Related]
20. Vitiligo treatment with monochromatic excimer light and tacrolimus: results of an open randomized controlled study. Nisticò S; Chiricozzi A; Saraceno R; Schipani C; Chimenti S Photomed Laser Surg; 2012 Jan; 30(1):26-30. PubMed ID: 22054204 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]